{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:59:29Z","timestamp":1774648769071,"version":"3.50.1"},"reference-count":64,"publisher":"Scientific Scholar","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2010]]},"DOI":"10.4103\/0378-6323.60541","type":"journal-article","created":{"date-parts":[[2010,4,10]],"date-time":"2010-04-10T06:21:48Z","timestamp":1270880508000},"page":"116","source":"Crossref","is-referenced-by-count":11,"title":["Antiphospholipid syndrome in dermatology: An update"],"prefix":"10.25259","volume":"76","author":[{"given":"Reena","family":"Rai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CShanmuga","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kumaresan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.60541-1","first-page":"20","volume-title":"The antiphospholipid syndrome: Immunologic and clinical aspects.Clinical spectrum and treatment","author":"Myones","year":"2000","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.60541-2","first-page":"48","volume-title":"Pierangeli SS, Gharavi AE, Harris EN.Testing for antiphospholipid antibodies: problems and solutions","author":"2","year":"2004","journal-title":"Clin Obstet Gynecol"},{"key":"key-10.4103\/0378-6323.60541-3","first-page":"632","volume-title":"Di\u00f3genes MJ, Di\u00f3genes PC, de Morais Carneiro RM, Neto CC, Duarte FB, Holanda RR.Cutaneous manifestations associated with antiphospholipid antibodies","author":"3","year":"2004","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0378-6323.60541-4","first-page":"745","volume-title":"Wassermann A, Neisser A, Bruck C.Eline serodiagnostiche Reaktion bei Syphilis","author":"4","year":"1906","journal-title":"Dtsch Med Wochenschr"},{"key":"key-10.4103\/0378-6323.60541-5","first-page":"484","volume-title":"Pangborn MC.A new serologically active phospholipid from beef heart","author":"5","year":"1941","journal-title":"Proc Soc Exp Biol Med"},{"key":"key-10.4103\/0378-6323.60541-6","first-page":"559","volume-title":"Haserick JR, Long R.Systemic Lupus erythematous preceded by false-positive serologic tests for syphilis; presentation of five cases","author":"6","year":"1952","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/0378-6323.60541-7","first-page":"1211","volume-title":"Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al.Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus","author":"7","year":"1983","journal-title":"Lancet"},{"key":"key-10.4103\/0378-6323.60541-8","first-page":"738","volume-title":"Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN.Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results","author":"8","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"key-10.4103\/0378-6323.60541-9","first-page":"486","volume-title":"Hughes GR, Harris NN, Gharavi AE.The anticardiolipin syndrome","author":"9","year":"1986","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.60541-10","first-page":"19","volume-title":"Harris EN, Baguley E, Asherson RA, Hughes GRV.Clinical and serological features of the antiphospholipid syndrome","author":"10","year":"1987","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.60541-11","first-page":"1742","volume-title":"Asherson RA.A \"primary\" antiphospholipid syndrome?","author":"11","year":"1988","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.60541-12","first-page":"1544","volume-title":"Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al.Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor","author":"12","year":"1990","journal-title":"Lancet"},{"key":"key-10.4103\/0378-6323.60541-13","first-page":"4120","volume-title":"McNeil HP, Simpson RJ, Chesterman CN, Krilis SA.Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: b2-glycoprotein I (apolipoprotein H)","author":"13","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/0378-6323.60541-14","first-page":"75","volume-title":"Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA.A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection","author":"14","year":"1992","journal-title":"Lupus"},{"key":"key-10.4103\/0378-6323.60541-15","first-page":"223","volume-title":"Arvieux J, Roussel B, Jacob MC, Colomb MG.Measurement of antiphospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen","author":"15","year":"1991","journal-title":"J Immunol Methods"},{"key":"key-10.4103\/0378-6323.60541-16","first-page":"1444","volume-title":"Roubey RA.Immunology of the antiphospholipid antibody syndrome","author":"16","year":"1996","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.60541-17","unstructured":"17. Lehninger AL. Lipid and membranes. In: Anderson S, Fox J, editors. Principles of biochemistry. New York: Worth Publishers; 1982. p. 303-29."},{"key":"key-10.4103\/0378-6323.60541-18","first-page":"1091","volume-title":"Hanly JG, Hong C, James H, Mansour M, Jones JV.Requirement of beta 2-glycoprotein 1 as cofactor in the binding of IgM and IgA anticardiolipin antibodies","author":"18","year":"1995","journal-title":"J Rhematol"},{"key":"key-10.4103\/0378-6323.60541-19","first-page":"405","volume-title":"Rao LVM, Permpikul P, Rapaport SI.Studies of the binding of lupus anticoagulant IgG to prothrombin, beta 2-glycoprotein 1 and phosphatidylserine","author":"19","year":"1993","journal-title":"Blood"},{"key":"key-10.4103\/0378-6323.60541-20","first-page":"2618","volume-title":"Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG.Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenic mechanism?","author":"20","year":"1993","journal-title":"Blood"},{"key":"key-10.4103\/0378-6323.60541-21","first-page":"761","volume-title":"Oosting JD, Preissner KT, Derksen RH, de Groot PG.Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro","author":"21","year":"1993","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0378-6323.60541-22","first-page":"159","volume-title":"Fillit H, Lahita R.Antibodies to vascular heparin sulfate proteoglycan in patients with systemic lupus erythematosus","author":"22","year":"1991","journal-title":"Autoimmunity"},{"key":"key-10.4103\/0378-6323.60541-23","first-page":"2532","volume-title":"Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H.Auto antibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of anti-thrombin III complexes","author":"23","year":"1994","journal-title":"Blood"},{"key":"key-10.4103\/0378-6323.60541-24","first-page":"55","volume-title":"Barquinero J, Ordi-Ros J, Selva A, Perez-Peman P, Vilardell M, Khamashta M.Antibodies against platelet-activating factor in patients with antiphospholipid antibodies","author":"24","year":"1994","journal-title":"Lupus"},{"key":"key-10.4103\/0378-6323.60541-25","first-page":"S44","volume-title":"Meroni PL, Del Papa N, Raschi E, Panzeri P, Borghi MO, Tincani A, et al.2-Glycoprotein I as a `cofactor\u2032 for anti- phospholipid reactivity with endothelial cells","author":"25","year":"1998","journal-title":"Lupus"},{"key":"key-10.4103\/0378-6323.60541-26","first-page":"237","volume-title":"Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, et al.Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome","author":"26","year":"2000","journal-title":"J Autoimmun"},{"key":"key-10.4103\/0378-6323.60541-27","first-page":"371","volume-title":"Ames PR.Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying membrane stress syndrome hypothesis","author":"27","year":"1994","journal-title":"Lupus"},{"key":"key-10.4103\/0378-6323.60541-28","first-page":"923","volume-title":"Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T.Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus","author":"28","year":"1993","journal-title":"Lancet"},{"key":"key-10.4103\/0378-6323.60541-29","first-page":"815","volume-title":"H\u00f6rkk\u00f6 S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, et al.Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein","author":"29","year":"1996","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0378-6323.60541-30","first-page":"271","volume-title":"Vlachoyiannopoulos PG, Samarkos M, Sikara M, Tsiligros P.Antiphospholipid antibodies: Laboratory and Pathogenetic Aspects","author":"30","year":"2007","journal-title":"Crit Rev Clin Lab Sci"},{"key":"key-10.4103\/0378-6323.60541-31","first-page":"22","volume-title":"de Groot PG, Derksen RH.Specificity and clinical relevance of lupus anticoagulant","author":"31","year":"1995","journal-title":"Vessels"},{"key":"key-10.4103\/0378-6323.60541-32","first-page":"1309","volume-title":"Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al.International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","author":"32","year":"1999","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.60541-33","first-page":"295","volume-title":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","author":"33","year":"2006","journal-title":"J Thromb Haemos"},{"key":"key-10.4103\/0378-6323.60541-34","first-page":"414","volume-title":"Sebastiani GD, Galeazzi M, Morozzi G, Marcolongo R.The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies and lupus anticoagulant","author":"34","year":"1996","journal-title":"Semin Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.60541-35","first-page":"145","volume-title":"Petri M.Epidemiology of the antiphospholipid antibody syndrome","author":"35","year":"2000","journal-title":"J Autoimmun"},{"key":"key-10.4103\/0378-6323.60541-36","first-page":"151","volume-title":"Antiphospholipid antibodies and reproduction","author":"36","year":"1997","journal-title":"J Reprod Immunol"},{"key":"key-10.4103\/0378-6323.60541-37","first-page":"129","volume-title":"Richaud-Patin Y, Cabiedes J, Jakez-Ocampo J, Vidaller A, Llorente L.High prevalence of protein-dependent and protein-independent antiphospholipid and other autoantibodies in healthy elders","author":"37","year":"2000","journal-title":"Thromb Res"},{"key":"key-10.4103\/0378-6323.60541-38","first-page":"576","volume-title":"Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP.The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue disease","author":"38","year":"1996","journal-title":"Am J Med"},{"key":"key-10.4103\/0378-6323.60541-39","first-page":"113","volume-title":"Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al.Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients","author":"39","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"key-10.4103\/0378-6323.60541-40","first-page":"1778","volume-title":"Alarc\u00f3n-Segovia D.Clinical manifestations of the antiphospholipid syndrome","author":"40","year":"1992","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.60541-41","first-page":"1019","volume-title":"Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","author":"41","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.60541-42","first-page":"3","volume-title":"Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, et al.Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients","author":"42","year":"1994","journal-title":"Am J Med"},{"key":"key-10.4103\/0378-6323.60541-43","first-page":"67","volume-title":"Weinstein S, Piette W.Cutaneous manifestations of antiphospholipid antibody syndrome","author":"43","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"key-10.4103\/0378-6323.60541-44","first-page":"41","volume-title":"Diallo M, Niang SO, Kane A, Dieng MT, Ndiaye B.Antiphospholipid antibodies syndrome in dermatology in Dakar: 11 case report","author":"44","year":"2007","journal-title":"Dakar Med"},{"key":"key-10.4103\/0378-6323.60541-45","first-page":"S46","volume-title":"Asherson RA, Franc\u00e8s C, Iaccarino L, Khamashta MA, Malacarne F, Piette JC, et al.The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy","author":"45","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"key-10.4103\/0378-6323.60541-46","first-page":"490","volume-title":"Kacalak-Rzepka A, Zaluga E, Maleszka R, Kr\u00f3licki A, Klimowicz A.Bullous systemic lupus erythematosus with antiphospholipid syndrome","author":"46","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.60541-47","first-page":"488","volume-title":"Elkayam O, Yaron M, Brazowski E, Caspi D.Rheumatoid nodules in a patient with primary antiphospholipid (Hughes) syndrome","author":"47","year":"1998","journal-title":"Lupus"},{"key":"key-10.4103\/0378-6323.60541-48","first-page":"331","volume-title":"Kuroda K, Mizoguchi M.Subcutaneous Granuloma pyogenicum in Patients with Antiphospholipid Antibodies","author":"48","year":"2004","journal-title":"Dermatology"},{"key":"key-10.4103\/0378-6323.60541-49","first-page":"814","volume-title":"Lee HW, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK","author":"49","year":"2005","journal-title":"Interstitial granulomatous dermatitis with plaques associated with antiphospholipid syndrome Br J Dermatol"},{"key":"key-10.4103\/0378-6323.60541-50","first-page":"397","volume-title":"Echigo T, Hasegawa M, Inaoki M, Yamazaki M, Sato S, Takehara K.Antiphospholipid antibodies in patients with autoimmune blistering disease","author":"50","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.60541-51","first-page":"499","volume-title":"Toubi E, Krause I, Fraser A, Lev S, Stojanovich L, Rovensky J, et al.Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome","author":"51","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key-10.4103\/0378-6323.60541-52","doi-asserted-by":"crossref","unstructured":"52. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000;160:2042-8.","DOI":"10.1001\/archinte.160.13.2042"},{"key":"key-10.4103\/0378-6323.60541-53","first-page":"2382","volume-title":"Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al.Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","author":"53","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.60541-54","first-page":"997","volume-title":"Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al.Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis","author":"54","year":"1992","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/0378-6323.60541-55","first-page":"1687","volume-title":"Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ.Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers","author":"55","year":"2008","journal-title":"Blood"},{"key":"key-10.4103\/0378-6323.60541-56","first-page":"103","volume-title":"Glasnovi\u00e6 M, Bosnjak I, Vcev A, Soldo I, Bedekovi\u00e6 D, Milakovi\u00e6 S, et al.Vascular thrombosis associated with antiphospholipide syndrome","author":"56","year":"2008","journal-title":"Coll Antropol"},{"key":"key-10.4103\/0378-6323.60541-57","first-page":"160","volume-title":"Erkan D, Lockshin MD.New approaches for managing antiphospholipidsyndrome","author":"57","year":"2009","journal-title":"Nat Clin Pract Rheumatol"},{"key":"key-10.4103\/0378-6323.60541-58","doi-asserted-by":"crossref","unstructured":"58. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Bri\u00ebt E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-62.","DOI":"10.1001\/archinte.1993.00410130073007"},{"key":"key-10.4103\/0378-6323.60541-59","first-page":"1716","volume-title":"al-Sayegh FA, Ensworth S, Huang S, Stein HB, Klinkhoff AV.Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome","author":"59","year":"1997","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.60541-60","first-page":"1133","volume-title":"Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al.A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","author":"60","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.60541-61","first-page":"1709","volume-title":"Dresang LT, Fontaine P, Leeman L, King VJ.Venous thromboembolism during pregnancy","author":"61","year":"2008","journal-title":"Am Fam Physician"},{"key":"key-10.4103\/0378-6323.60541-62","first-page":"684","volume-title":"Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J.Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin","author":"62","year":"2005","journal-title":"Fertil Steril"},{"key":"key-10.4103\/0378-6323.60541-63","doi-asserted-by":"crossref","unstructured":"63 Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119:300S-20","DOI":"10.1378\/chest.119.1_suppl.300S"},{"key":"key-10.4103\/0378-6323.60541-64","first-page":"478","volume-title":"Horn HC, Grau K, Junker P.IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome","author":"64","year":"2004","journal-title":"Lupus"}],"container-title":["Indian Journal of Dermatology, Venereology, and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T00:44:49Z","timestamp":1612658689000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/antiphospholipid-syndrome-in-dermatology-an-update\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"alternative-id":["60541"],"URL":"https:\/\/doi.org\/10.4103\/0378-6323.60541","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}